Volume 17, Number 10—October 2011
Dispatch
Extensively Drug-Resistant Tuberculosis in Women, KwaZulu-Natal, South Africa
Max R. O’Donnell
, Jennifer Zelnick, Lise Werner, Iqbal Master, Marian Loveday, C. Robert Horsburgh, and Nesri Padayatchi
, Jennifer Zelnick, Lise Werner, Iqbal Master, Marian Loveday, C. Robert Horsburgh, and Nesri Padayatchi
Table A1
Trends in hospital admissions for MDR TB and XDR TB and HIV prevalence among adults >18 years admitted to King George V Hospital, KwaZulu-Natal, South Africa*
| MDR TB patients | XDR TB patients | HIV prevalence† | ||||
|---|---|---|---|---|---|---|
| Year of hospital admission | Male, no. (%), n = 2,150 | Female, no. (%), n = 1,987 | Male, no. (%), n = 155 | Female, no. (%), n = 222 | Male, no. (%), n = 1,083 | Female, no. (%), n = 1,431 |
| 2003 | 275 (59.8) | 185 (40.2) | 3 (50.0) | 3 (50.0) | 80 (51) | 64 (74) |
| 2004 | 231 (54.5) | 193 (45.5) | 2 (40.0) | 3 (60.0) | 82 (55) | 94 (72) |
| 2005 | 268 (51.6) | 251 (48.4) | 15 (41.7) | 21 (58.3) | 126 (63) | 159 (75) |
| 2006 | 321 (51.0) | 309 (49.0) | 29 (37.2) | 49 (62.3) | 143 (61) | 221 (76) |
| 2007 | 532 (50.9) | 514 (49.1) | 61 (44.5) | 76 (55.5) | 331 (66) | 432 (81) |
| 2008 | 523 (49.4) | 535 (50.61) | 45 (39.1) | 70 (60.9) | 321 (66) | 461 (81) |
| Cochran-Armitage test for trend, p value | <0.001 | 0.68 | <0.001 | 0.003
*MDR TB, multidrug-resistant tuberculosis; XDR TB, extensively drug-resistant tuberculosis. †HIV prevalence among MDR TB and XDR TB patients with known HIV test results. | ||
*MDR TB, multidrug-resistant tuberculosis; XDR TB, extensively drug-resistant tuberculosis.
†HIV prevalence among MDR TB and XDR TB patients with known HIV test results.
Page created: September 26, 2011
Page updated: September 26, 2011
Page reviewed: September 26, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.